Orbifloxacin | CAS# 113617-63-3 | Antibiotic

MedKoo Cat#: 564421 | Name: Orbifloxacin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Orbifloxacin is an antibiotic which is effective against most Gram-negative bacteria, including Enterobacteriaceae and Pseudomonas. Orbifloxacin suppressed growth of the Pa12 brmts.

Chemical Structure

Orbifloxacin

CAS#113617-63-3

Theoretical Analysis

MedKoo Cat#: 564421

Name: Orbifloxacin

CAS#: 113617-63-3

Chemical Formula: C19H20F3N3O3

Exact Mass: 395.1457

Molecular Weight: 395.38

Elemental Analysis: C, 57.72; H, 5.10; F, 14.42; N, 10.63; O, 12.14

Price and Availability

Size	Price	Availability	Quantity
50mg	USD 415.00
100mg	USD 555.00
250mg	USD 800.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Orbax; Orbifloxacin

IUPAC/Chemical Name

1-Cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic acid

InChi Key

QIPQASLPWJVQMH-DTORHVGOSA-N

InChi Code

InChI=1S/C19H20F3N3O3/c1-8-5-24(6-9(2)23-8)17-14(21)13(20)12-16(15(17)22)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6H2,1-2H3,(H,27,28)/t8-,9+

SMILES Code

O=C(C1=CN(C2CC2)C3=C(C(F)=C(F)C(N4C[C@H](C)N[C@H](C)C4)=C3F)C1=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Orbifloxacin is a synthetic broad-spectrum fluoroquinolone antibiotic which is approved for use in dogs.

In vitro activity:

Orbifloxacin was tested at different concentrations for killing rate against five isolates obtained from pyoderma cases and against a reference strain (Staphylococcus aureus ATCC 29213). Orbifloxacin expressed a concentration-dependent bactericidal activity against the S. aureus reference strain, but a time-dependent bactericidal activity against S. intermedius. Orbifloxacin induced bactericidal effect against the S. intermedius strains tested with concentrations equal to or two times MIC. Reference: Res Vet Sci. 2004 Aug;77(1):67-71. https://pubmed.ncbi.nlm.nih.gov/15120955/

In vivo activity:

Administration of orbifloxacin in E. coli-infected mice modulated the effects of infection on the percentage of phagocyting macrophages, the percentage of NBT-positive cells, and nitric oxide production. Orbifloxacin did not affect the synthesis and release of interleukin-1 by macrophages. Orbifloxacin exerted a modulating effect on the subsets of lymphocytes in thymus, spleen, and mesenteric lymph node cells in noninfected and E. coli-infected mice. Reference: Immunopharmacol Immunotoxicol. 2005;27(3):461-72. https://pubmed.ncbi.nlm.nih.gov/16237956/

	Solvent	mg/mL	mM
Solubility
	DMF	10.0	25.29
	DMF:PBS (pH 7.2) (1:1)	0.5	1.26
	DMSO	3.0	7.65

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 395.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zhou W, Yang B, Zou Y, Rahman K, Cao X, Lei Y, Lai R, Fu ZF, Chen X, Cao G. Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates. Front Microbiol. 2021 Jun 30;12:658637. doi: 10.3389/fmicb.2021.658637. PMID: 34276592; PMCID: PMC8278749. 2. Ganière JP, Médaille C, Etoré F. In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections. Res Vet Sci. 2004 Aug;77(1):67-71. doi: 10.1016/j.rvsc.2004.02.002. PMID: 15120955. 3. Szczypka M, Gaweda B, Obmińska-Mrukowicz B. Modulation of cellular immune response by orbifloxacin in noninfected and E. coli-infected mice. Immunopharmacol Immunotoxicol. 2005;27(3):461-72. doi: 10.1080/08923970500241303. PMID: 16237956.

In vitro protocol:

In vivo protocol:

1: Harada K, Miyamoto T, Sugiyama M, Asai T. First report of a blaNDM-5-carrying Escherichia coli sequence type 12 isolated from a dog with pyometra in Japan. J Infect Chemother. 2024 Sep;30(9):938-941. doi: 10.1016/j.jiac.2024.02.013. Epub 2024 Feb 16. PMID: 38369122. 2: Maroto-Tello A, Ayllón T, Aguinaga-Casañas MA, Ariza JJ, Penelo S, Baños A, Ortiz-Díez G. In Vitro Activity of Allium cepa Organosulfur Derivatives against Canine Multidrug-Resistant Strains of Staphylococcus spp. and Enterobacteriaceae. Vet Sci. 2024 Jan 9;11(1):26. doi: 10.3390/vetsci11010026. PMID: 38250932; PMCID: PMC10820550. 3: Parvathy K. Resolution of hypoalbuminemia in a 3-year-old hound-mix dog after discontinuation of oclacitinib. J Am Vet Med Assoc. 2023 Dec 8;262(3):1-3. doi: 10.2460/javma.23.10.0600. PMID: 38064895. 4: Shimada S, Aboubakr M, Elbadawy M, Usui T, Sasaki K, Shimoda M. Biliary excretion and pharmacokinetics of several fluoroquinolones after intravenous injection in rabbits. J Vet Med Sci. 2023 Oct 19;85(10):1099-1105. doi: 10.1292/jvms.23-0246. Epub 2023 Aug 25. PMID: 37635088; PMCID: PMC10600534. 5: Beltrán JF, Yáñez A, Herrera-Belén L, Contreras FP, Blanco JA, Flores-Martin SN, Zamorano M, Farias JG. Antibiotic discovery against Piscirickettsia salmonis using a combined in silico and in vitro approach. Microb Pathog. 2023 Jul;180:106122. doi: 10.1016/j.micpath.2023.106122. Epub 2023 Apr 22. PMID: 37094756. 6: Abbas MA, Lee EB, Boby N, Biruhanu BT, Park SC. A pharmacodynamic investigation to assess the synergism of orbifloxacin and propyl gallate against Escherichia coli. Front Pharmacol. 2022 Sep 15;13:989395. doi: 10.3389/fphar.2022.989395. PMID: 36188537; PMCID: PMC9521280. 7: Ekakoro JE, Hendrix GK, Guptill LF, Ruple A. Antimicrobial susceptibility and risk factors for resistance among Escherichia coli isolated from canine specimens submitted to a diagnostic laboratory in Indiana, 2010-2019. PLoS One. 2022 Aug 24;17(8):e0263949. doi: 10.1371/journal.pone.0263949. PMID: 36001634; PMCID: PMC9401157. 8: Zhou J, Chen A, Guo H, Li Y, He X, Chen L, Zhang Y. Covalent Organic Framework/Polyacrylonitrile Electrospun Nanofiber for Dispersive Solid-Phase Extraction of Trace Quinolones in Food Samples. Nanomaterials (Basel). 2022 Jul 20;12(14):2482. doi: 10.3390/nano12142482. PMID: 35889706; PMCID: PMC9319950. 9: KuKanich KS, Bagladi-Swanson M, KuKanich B. Pseudomonas aeruginosa susceptibility, antibiogram and clinical interpretation, and antimicrobial prescribing behaviors for dogs with otitis in the Midwestern United States. J Vet Pharmacol Ther. 2022 Sep;45(5):440-449. doi: 10.1111/jvp.13077. Epub 2022 Jun 13. PMID: 35698441. 10: Nishi R, Ohmi A, Tsuboi M, Yamamoto K, Tomiyasu H. Successful treatment of a lung abscess without surgical intervention in a cat. JFMS Open Rep. 2022 Mar 25;8(1):20551169221086434. doi: 10.1177/20551169221086434. PMID: 35356306; PMCID: PMC8958698. 11: Yang F, Liu D, Yang C, Song ZW, Shao HT, Zhang M, Zhang CS, Zhang ZD, Yang F. Development and application of a physiologically based pharmacokinetic model for orbifloxacin in crucian carp (Carassius auratus). J Vet Pharmacol Ther. 2022 May;45(3):311-319. doi: 10.1111/jvp.13049. Epub 2022 Mar 4. PMID: 35243644. 12: Kuramae T, Ishikawa S, Kono A, Hobo S. Pharmacokinetics in plasma and alveolar regions of a healthy calf intramuscularly administered a single dose of orbifloxacin. J Vet Med Sci. 2022 Mar 15;84(3):400-405. doi: 10.1292/jvms.21-0517. Epub 2022 Jan 28. PMID: 35095059; PMCID: PMC8983296. 13: Nakamura K, Fujiki J, Nakamura T, Furusawa T, Gondaira S, Usui M, Higuchi H, Tamura Y, Iwano H. Fluctuating Bacteriophage-induced galU Deficiency Region is Involved in Trade-off Effects on the Phage and Fluoroquinolone Sensitivity in Pseudomonas aeruginosa. Virus Res. 2021 Dec;306:198596. doi: 10.1016/j.virusres.2021.198596. Epub 2021 Oct 12. PMID: 34648885. 14: Zhou W, Yang B, Zou Y, Rahman K, Cao X, Lei Y, Lai R, Fu ZF, Chen X, Cao G. Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates. Front Microbiol. 2021 Jun 30;12:658637. doi: 10.3389/fmicb.2021.658637. PMID: 34276592; PMCID: PMC8278749. 15: Oguttu JW, Qekwana DN, Odoi A. Prevalence and Predictors of Antimicrobial Resistance Among Enterococcus spp. From Dogs Presented at a Veterinary Teaching Hospital, South Africa. Front Vet Sci. 2021 Jan 7;7:589439. doi: 10.3389/fvets.2020.589439. PMID: 33490130; PMCID: PMC7817767. 16: Malka S, Goller M, Dennison-Gibby S. Septic Arthritis and Osteomyelitis Caused by Chryseobacterium indologenes in a Mute Swan (Cygnus olor) and a Ring-Billed Gull (Larus delawarensis). J Avian Med Surg. 2020 Oct 20;34(3):289-294. doi: 10.1647/1082-6742-34.3.289. PMID: 33099983. 17: Eliasi UL, Sebola D, Oguttu JW, Qekwana DN. Antimicrobial resistance patterns of Pseudomonas aeruginosa isolated from canine clinical cases at a veterinary academic hospital in South Africa. J S Afr Vet Assoc. 2020 Sep 22;91(0):e1-e6. doi: 10.4102/jsava.v91i0.2052. PMID: 33054249; PMCID: PMC7564669. 18: Rodriguez-Mozaz S, Vaz-Moreira I, Varela Della Giustina S, Llorca M, Barceló D, Schubert S, Berendonk TU, Michael-Kordatou I, Fatta-Kassinos D, Martinez JL, Elpers C, Henriques I, Jaeger T, Schwartz T, Paulshus E, O'Sullivan K, Pärnänen KMM, Virta M, Do TT, Walsh F, Manaia CM. Antibiotic residues in final effluents of European wastewater treatment plants and their impact on the aquatic environment. Environ Int. 2020 Jul;140:105733. doi: 10.1016/j.envint.2020.105733. Epub 2020 Apr 27. PMID: 32353669. 19: Iyama Y, Sato H, Seto Y, Onoue S. Strategic photosafety screening system consisting of in chemico photoreactivity and in vitro skin exposure for quinolone derivatives. Eur J Pharm Sci. 2020 Apr 15;146:105257. doi: 10.1016/j.ejps.2020.105257. Epub 2020 Feb 5. PMID: 32035110. 20: Yang YR, Yang F, Sun N, Wang GY. Disposition kinetics of orbifloxacin in tissues of crucian carp (Carassius auratus) following a single intramuscular administration. Iran J Vet Res. 2019 Spring;20(2):131-135. PMID: 31531036; PMCID: PMC6716280.